Health News

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, gene, Pharmacy, Tumor

Related posts

• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• New strategy can reactivate genes that cause cancer tumors to shrink and die (0)
  A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs. Read more [tags] Pharmacy News [/tags]
  
  
• FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment (0)
  The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of [...]
  
  
• Cost-effectiveness of Cetuximab in metastatic colorectal cancer (0)
  From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute. Read more [tags] Pharmacy News [/tags]
  
  
• Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene (0)
  In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically [...]